Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results.

Behan M, O'Connell D, Mattrey RF, Carney DN.

AJR Am J Roentgenol. 1993 Feb;160(2):399-405.

PMID:
8424361
[PubMed - indexed for MEDLINE]
2.

Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide.

Bruneton JN, Falewée MN, François E, Cambon P, Philip C, Riess JG, Balu-Maestro C, Rogopoulos A.

Radiology. 1989 Jan;170(1 Pt 1):179-83.

PMID:
2909093
[PubMed - indexed for MEDLINE]
3.

Computed tomographic enhancement of the liver, liver abscesses, spleen, and major vessels with perfluorooctylbromide emulsion. Influence of dosage and injection velocity in an animal model.

Adam G, Günther RW, Schiffer C, Görtz H, Prescher A, Scherer K.

Invest Radiol. 1992 Sep;27(9):698-705.

PMID:
1399453
[PubMed - indexed for MEDLINE]
4.

Time versus density enhancement of liver, spleen, and great vessels following rapid intravenous infusion of perflubron emulsion.

Harned RK 2nd, Fruman SA, Swenson RB, Bernardino ME.

Acad Radiol. 1995 Jan;2(1):38-42.

PMID:
9419522
[PubMed - indexed for MEDLINE]
5.

Nanoscaled iodized oil emulsion as a CT contrast agent for the detection of experimental liver tumors in a rat model.

Lim SJ, Lim JS, Choi J, Choi JY, Hyung WJ, Kim HS, Suh J, Kim KW.

Acad Radiol. 2010 Aug;17(8):985-91. doi: 10.1016/j.acra.2010.03.021.

PMID:
20617548
[PubMed - indexed for MEDLINE]
6.

Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results.

Mattrey RF, Strich G, Shelton RE, Gosink BB, Leopold GR, Lee T, Forsythe J.

Radiology. 1987 May;163(2):339-43.

PMID:
3550878
[PubMed - indexed for MEDLINE]
7.

Using a saline chaser to decrease contrast media in abdominal CT.

Dorio PJ, Lee FT Jr, Henseler KP, Pilot M, Pozniak MA, Winter TC 3rd, Shock SA.

AJR Am J Roentgenol. 2003 Apr;180(4):929-34.

PMID:
12646431
[PubMed - indexed for MEDLINE]
8.

Perfluoroctylbromide as a blood pool contrast agent for liver, spleen, and vascular imaging in computed tomography.

Mattrey RF, Long DM, Peck WW, Slutsky RA, Higgins CB.

J Comput Assist Tomogr. 1984 Aug;8(4):739-44.

PMID:
6736376
[PubMed - indexed for MEDLINE]
9.

MDCT of the liver and hypervascular hepatocellular carcinomas: optimizing scan delays for bolus-tracking techniques of hepatic arterial and portal venous phases.

Goshima S, Kanematsu M, Kondo H, Yokoyama R, Miyoshi T, Nishibori H, Kato H, Hoshi H, Onozuka M, Moriyama N.

AJR Am J Roentgenol. 2006 Jul;187(1):W25-32.

PMID:
16794136
[PubMed - indexed for MEDLINE]
10.

Efficacy of Imagent BP at 1.5ml/kg in a rabbit liver tumor model.

Baker KG, Wrigley R, Saunders HB, Mattrey RF.

Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1491-9.

PMID:
7849962
[PubMed - indexed for MEDLINE]
11.

Contrast-enhanced CT of the liver and spleen: comparison of ionic and nonionic contrast agents.

Nelson RC, Chezmar JL, Peterson JE, Bernardino ME.

AJR Am J Roentgenol. 1989 Nov;153(5):973-6.

PMID:
2801447
[PubMed - indexed for MEDLINE]
12.

Distinction between cavernous hemangiomas of the liver and hepatic metastases on CT: value of contrast enhancement patterns.

Leslie DF, Johnson CD, Johnson CM, Ilstrup DM, Harmsen WS.

AJR Am J Roentgenol. 1995 Mar;164(3):625-9.

PMID:
7863883
[PubMed - indexed for MEDLINE]
13.

Real-time contrast-enhanced ultrasound of the spleen: examination technique and preliminary clinical experience.

Catalano O, Lobianco R, Sandomenico F, D'Elia G, Siani A.

Radiol Med. 2003 Oct;106(4):338-56. English, Italian.

PMID:
14612826
[PubMed - indexed for MEDLINE]
14.

Hepatic enhancement and metastatic lesion conspicuity on CT scans: influence of intravenous glucagon and oral CT contrast material.

Warshauer DM, Wehmueller MD, Molina PL, Muller KE, DeLuca MC, Lee JK.

Radiology. 1997 Feb;202(2):394-8.

PMID:
9015064
[PubMed - indexed for MEDLINE]
15.

Perfluoroctylbromide and hepatosplenic computed tomography. Preliminary clinical study.

Bruneton JN, Falewee MN, Balu-Maestro C, Normand F, Mattrey RF.

Invest Radiol. 1988 Sep;23 Suppl 1:S306-7.

PMID:
3198367
[PubMed - indexed for MEDLINE]
16.

Perfluoroctylbromide: a reticuloendothelial-specific and tumor-imaging agent for computed tomography.

Mattrey RF, Long DM, Multer F, Mitten R, Higgins CB.

Radiology. 1982 Dec;145(3):755-8.

PMID:
7146408
[PubMed - indexed for MEDLINE]
17.

Phase-inversion sonography during the liver-specific late phase of contrast enhancement: improved detection of liver metastases.

Albrecht T, Hoffmann CW, Schmitz SA, Schettler S, Overberg A, Germer CT, Wolf KJ.

AJR Am J Roentgenol. 2001 May;176(5):1191-8.

PMID:
11312180
[PubMed - indexed for MEDLINE]
18.

Conspicuity of hepatic metastases on helical CT: effect of different time delays between contrast administration and scanning.

Silverman PM, O'Malley J, Tefft MC, Cooper C, Zeman RK.

AJR Am J Roentgenol. 1995 Mar;164(3):619-23.

PMID:
7863882
[PubMed - indexed for MEDLINE]
19.

Clinical trials with a new iodinated lipid emulsion for computed tomography of the liver.

Ivancev K, Lunderquist A, Isaksson A, Hochbergs P, Wretlind A.

Acta Radiol. 1989 Sep-Oct;30(5):449-57.

PMID:
2558697
[PubMed - indexed for MEDLINE]
20.

Multiple-phase helical CT of the liver for detecting small hepatomas in patients with liver cirrhosis: contrast-injection protocol and optimal timing.

Mitsuzaki K, Yamashita Y, Ogata I, Nishiharu T, Urata J, Takahashi M.

AJR Am J Roentgenol. 1996 Sep;167(3):753-7.

PMID:
8751695
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk